共 155 条
[1]
Blumberg HM(2003)American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 167 603-662
[2]
Burman WJ(2003)Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 1472-1477
[3]
Chaisson RE(1990)Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver J Biol Chem 265 12757-12760
[4]
Daley CL(1995)Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity Am J Hum Genet 57 581-592
[5]
Etkind SC(2002)Pharmacogenetics of the arylamine N-acetyltransferases Pharmacogenomics J 2 30-42
[6]
Friedman LN(1997)Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis Am J Respir Crit Care Med 155 1717-1722
[7]
Fujiwara P(2000)Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity Int J Tuberc Lung Dis 4 256-261
[8]
Grzemska M(2002)Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis Hepatology 35 883-889
[9]
Hopewell PC(2006)DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity Tuberculosis (Edinb) 86 374-381
[10]
Iseman MD(1998)Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients Chest 113 1178-1183